Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

High Concentration of Dezocine Induces Immune Escape of Lung Cancer and Promotes Glucose Metabolism through Up-Regulating PD-L1 and Activating the NF-κB Pathway

Author(s): Weiping Dong, Dong Zhang, Aiyun Zhu, Yanli Hu and Wei Li*

Volume 22, Issue 10, 2022

Published on: 13 January, 2022

Page: [919 - 928] Pages: 10

DOI: 10.2174/1566524022666211222155118

Price: $65

Abstract

Background: Dezocine is an opioid analgesic that can affect the immune system. Here, we explored the synergy of high concentration of Dezocine and programmed death-ligand 1 (PD-L1) with regards to immune escape and glucose metabolism in lung cancer (LC).

Methods: PD-L1 level in human LC cell lines was determined and the influence of Dezocine at different concentrations for the proliferation of LC cells was identified. Next, LC cells were transfected to alter PD-L1 level, and exposed to Dezocine at 8 μg/mL to explore their effects on cell proliferation, production of interferon-γ (IFN-γ), contents of glucose, lactate, and NADPH/NADP+, and activation of the nuclear factor-κB (NF-κB) pathway.

Results: PD-L1 level was increased in LC cells and Dezocine (8 μg/mL) impaired the proliferation of LC cells. Down-regulating PD-L1 inhibited cell proliferation, enhanced production of IFN-γ, and reduced the contents of glucose, lactate, and NADPH/NADP+, while up-regulating PD-L1 caused the opposite results. Dezocine (8 μg/mL) induced immune escape and glucose metabolism in LC, and Dezocine-induced effects were reversed by down-regulating PD-L1. Dezocine (8 μg/mL) up-regulated PD-L1 by activating the NF-κB pathway.

Conclusion: Dezocine at 8 μg/mL promotes immune escape and glucose metabolism in LC through up-regulating PD-L1 and activating the NF-κB pathway.

Keywords: Lung cancer, dezocine, programmed death-ligand 1, nuclear factor-κB pathway, proliferation, immune escape, glucose consumption.

« Previous Next »
[1]
Nasim F, Sabath BF, Eapen GA. Lung Cancer. Med Clin North Am 2019; 103(3): 463-73.
[http://dx.doi.org/10.1016/j.mcna.2018.12.006] [PMID: 30955514]
[2]
Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med 2020; 41(1): 1-24.
[http://dx.doi.org/10.1016/j.ccm.2019.10.001] [PMID: 32008623]
[3]
Hoy H, Lynch T, Beck M. Surgical treatment of lung cancer. Crit Care Nurs Clin North Am 2019; 31(3): 303-13.
[http://dx.doi.org/10.1016/j.cnc.2019.05.002] [PMID: 31351552]
[4]
Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med (Lond) 2018; 18(Suppl. 2): s41-6.
[http://dx.doi.org/10.7861/clinmedicine.18-2-s41] [PMID: 29700092]
[5]
Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet 2017; 389(10066): 299-311.
[http://dx.doi.org/10.1016/S0140-6736(16)30958-8] [PMID: 27574741]
[6]
Ilie M, Benzaquen J, Hofman V, et al. Immunotherapy in non-small cell lung cancer: Biological principles and future opportunities. Curr Mol Med 2017; 17(8): 527-40.
[http://dx.doi.org/10.2174/1566524018666180222114038] [PMID: 29473504]
[7]
Boland JW, Pockley AG. Influence of opioids on immune function in patients with cancer pain: from bench to bedside. Br J Pharmacol 2018; 175(14): 2726-36.
[http://dx.doi.org/10.1111/bph.13903] [PMID: 28593737]
[8]
Zhou ZG, Liu R, Tan HL, Ji XY, Yi XL, Song JF. The application of dexmedetomidine combined with dezocine in thoracoscopic radical resection of lung cancer and its effect on awakening quality of patients. Eur Rev Med Pharmacol Sci 2019; 23(17): 7694-702.
[PMID: 31539162]
[9]
Wang F, Zhang X, Wang H, Liu Y. Effects of dezocine and sufentanyl for postoperative analgesia on activity of NK, CD4+ and CD8+ cells in patients with breast cancer. Oncol Lett 2019; 17(3): 3392-8.
[http://dx.doi.org/10.3892/ol.2019.9964] [PMID: 30867775]
[10]
Zhong ZW, Zhou WC, Sun XF, Wu QC, Chen WK, Miao CH. Dezocine regulates the malignant potential and aerobic glycolysis of liver cancer targeting Akt1/GSK-3β pathway. Ann Transl Med 2020; 8(7): 480.
[http://dx.doi.org/10.21037/atm.2020.03.28] [PMID: 32395524]
[11]
Wang L, Ma Q, Yao R, Liu J. Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. Int Immunopharmacol 2020; 79: 106088.
[http://dx.doi.org/10.1016/j.intimp.2019.106088] [PMID: 31896512]
[12]
Peng S, Wang R, Zhang X, et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer 2019; 18(1): 165.
[http://dx.doi.org/10.1186/s12943-019-1073-4] [PMID: 31747941]
[13]
Miyazawa T, Marushima H, Saji H, et al. PD-L1 expression in non-small-cell lung cancer including various adenocarcinoma subtypes. Ann Thorac Cardiovasc Surg 2019; 25(1): 1-9.
[http://dx.doi.org/10.5761/atcs.oa.18-00163] [PMID: 30282880]
[14]
Antonangeli F, Natalini A, Garassino MC, Sica A, Santoni A, Di Rosa F. Regulation of PD-L1 expression by NF-κB in cancer. Front Immunol 2020; 11: 584626.
[http://dx.doi.org/10.3389/fimmu.2020.584626] [PMID: 33324403]
[15]
Yu M, Qi B, Xiaoxiang W, Xu J, Liu X. Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathway. Biomed Pharmacother 2017; 90: 677-85.
[http://dx.doi.org/10.1016/j.biopha.2017.04.001] [PMID: 28415048]
[16]
El-Nikhely N, Karger A, Sarode P, et al. Metastasis-associated protein 2 represses NF-κB to reduce lung tumor growth and inflammation. Cancer Res 2020; 80(19): 4199-211.
[http://dx.doi.org/10.1158/0008-5472.CAN-20-1158] [PMID: 32816854]
[17]
Jin X, Ding D, Yan Y, et al. Phosphorylated RB promotes cancer immunity by inhibiting nf-κb activation and PD-L1 expression. Mol Cell 2019; 73(1): 22-35.e6.
[http://dx.doi.org/10.1016/j.molcel.2018.10.034] [PMID: 30527665]
[18]
Yu Y, Liang Y, Li D, et al. Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment. Cell Death Discov 2021; 7(1): 15.
[http://dx.doi.org/10.1038/s41420-021-00401-7] [PMID: 33462221]
[19]
Vincent-Fabert C, Roland L, Zimber-Strobl U, Feuillard J, Faumont N. Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma. Cell Commun Signal 2019; 17(1): 89.
[http://dx.doi.org/10.1186/s12964-019-0391-x] [PMID: 31382969]
[20]
Garland WA, Barbalas MP. Applications to analytic chemistry: an evaluation of stable isotopes in mass spectral drug assays. J Clin Pharmacol 1986; 26(6): 412-8.
[http://dx.doi.org/10.1002/j.1552-4604.1986.tb03550.x] [PMID: 2942579]
[21]
Song Q, Liu G, Liu D, Feng C. Dezocine promotes T lymphocyte activation and inhibits tumor metastasis after surgery in a mouse model. Invest New Drugs 2020; 38(5): 1342-9.
[http://dx.doi.org/10.1007/s10637-020-00921-6] [PMID: 32170576]
[22]
Li P, Huang T, Zou Q, et al. FGFR2 promotes expression of PD-L1 in colorectal cancer via the JAK/STAT3 signaling pathway. J Immunol 2019; 202(10): 3065-75.
[http://dx.doi.org/10.4049/jimmunol.1801199] [PMID: 30979816]
[23]
Cao D, Qi Z, Pang Y, et al. Retinoic acid-related orphan receptor C regulates proliferation, glycolysis, and chemoresistance via the PD-L1/ITGB6/STAT3 signaling axis in bladder cancer. Cancer Res 2019; 79(10): 2604-18.
[http://dx.doi.org/10.1158/0008-5472.CAN-18-3842] [PMID: 30808674]
[24]
Kim DH, Kim H, Choi YJ, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Exp Mol Med 2019; 51(8): 1-13.
[http://dx.doi.org/10.1038/s12276-019-0295-2] [PMID: 31399559]
[25]
Cai H, Yan L, Liu N, Xu M, Cai H. IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway. Biomed Pharmacother 2020; 123: 109790.
[http://dx.doi.org/10.1016/j.biopha.2019.109790] [PMID: 31896065]
[26]
Shang A, Wang W, Gu C, et al. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils. J Exp Clin Cancer Res 2019; 38(1): 411.
[http://dx.doi.org/10.1186/s13046-019-1394-6] [PMID: 31533774]
[27]
Ma P, Xing M, Han L, et al. High PD L1 expression drives glycolysis via an Akt/mTOR/HIF 1α axis in acute myeloid leukemia. Oncol Rep 2020; 43(3): 999-1009.
[http://dx.doi.org/10.3892/or.2020.7477] [PMID: 32020232]
[28]
Wang S, Li J, Xie J, et al. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway. Oncogene 2018; 37(30): 4164-80.
[http://dx.doi.org/10.1038/s41388-018-0252-x] [PMID: 29706653]
[29]
Li H, Xia JQ, Zhu FS, et al. LPS promotes the expression of PD-L1 in gastric cancer cells through NF-κB activation. J Cell Biochem 2018; 119(12): 9997-10004.
[http://dx.doi.org/10.1002/jcb.27329] [PMID: 30145830]
[30]
Hu M, Yang J, Qu L, et al. Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-κB pathway in lung adenocarcinoma. Food Funct 2020; 11(1): 456-71.
[http://dx.doi.org/10.1039/C9FO02166C] [PMID: 31830168]

Rights & Permissions Print Cite
Article Metrics
28
1
© 2024 Bentham Science Publishers | Privacy Policy